Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000674413 | SCV000799746 | uncertain significance | Galactosylceramide beta-galactosidase deficiency | 2018-05-03 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV003133503 | SCV003816288 | uncertain significance | not provided | 2020-08-30 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003489796 | SCV004241989 | uncertain significance | not specified | 2023-12-08 | criteria provided, single submitter | clinical testing | Variant summary: GALC c.486C>A (p.Asp162Glu) results in a conservative amino acid change located in the Glycosyl hydrolase family 59, catalytic domain of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 8e-06 in 249478 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.486C>A has been reported in the literature in two siblings with multiple sclerosis who inherited the variant from their mother who was neurologically normal (Traboulsee_2017). These reports do not provide unequivocal conclusions about association of the variant with Krabbe Disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. |